Depomed (NASDAQ:DEPO) : During the past 4 weeks, traders have been relatively bearish on Depomed (NASDAQ:DEPO), hence the stock is down -6.8% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.54% relative to the S&P 500. The 4-week change in the price of the stock is -5.3% and the stock has fallen -5.35% in the past 1 week.
The company shares have dropped -38.48% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $33.74 and the one year low was seen on Mar 24, 2016. The 50-Day Moving Average price is $19.82 and the 200 Day Moving Average price is recorded at $17.06.
The stock has recorded a 20-day Moving Average of 3.97% and the 50-Day Moving Average is 1.71%.
Depomed (NASDAQ:DEPO): stock turned positive on Friday. Though the stock opened at $18.77, the bulls momentum made the stock top out at $18.96 level for the day. The stock recorded a low of $18.69 and closed the trading day at $18.77, in the green by 0.05%. The total traded volume for the day was 1,535,020. The stock had closed at $18.76 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Vargas Thadd M, officer (Senior VP, BD) of Depomed Inc, had unloaded 15,000 shares at an average price of $20 in a transaction dated on May 23, 2016. The total value of the transaction was worth $300,000.
Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinsons disease.